New directions in cancer therapy

Helix BioPharma Corporation is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. Helix is currently listed on TSX and FSE under the symbol “HBP”

home_image

DOS47

Our most innovative technological platform for the treatment of solid tumors

News

May 30, 2015

L-DOS47 Research Paper Published in an ACS Journal

Production and Characterization of a Camelid Single Domain Antibody−Urease Enzyme Conjugate for the Treatment of Cancer

May 27, 2015

HELIX BIOPHARMA CORP. Announces a Presentation at the Joint Conference of The Canadian Society For Pharmaceutical Science and The Canadian Chapter of the Controlled Release Society

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company
developing innovative drug candidates for the prevention and treatment of cancer, today announced that its Chief Scientific Officer, Dr. Heman Chao, has been invited to give an oral presentation at the 2015 Joint Conference of the Canadian Society For Pharmaceutical Science and the Canadian Chapter of the Controlled Release Society.

April 7, 2015

HBP Press Release – Initiates Enrollment for Twelvth Cohort in Polish Phase I,II Clinical Study

HBP Press Release – Initiates Enrollment for Twelvth Cohort in Polish Phase I,II Clinical Study

March 16, 2015

HBP Press Release – Receipt of net CAD5.2mil Private Placement Subscriptions

HBP Press Release – Receipt of net CAD5.2mil Private Placement Subscriptions

March 11, 2015

Corporate Presentation March 2015

Helix Corporate Presentation MARCH 2015

March 10, 2015

HBP Press Release – Q2 Fiscal 2015 Results

HBP Press Release – Q2 Fiscal 2015 Results

February 17, 2015

HBP Press Release – Initiates Enrollment for Eleventh Cohort in Polish Phase I,II Clinical Study

HBP Press Release – Initiates Enrollment for Eleventh Cohort in Polish Phase I,II Clinical Study

December 22, 2014

HBP Press Release – Initiates First Clinical Site for US Study

HBP Press Release – Initiates First Clinical Site for US Study

December 18, 2014

HBP Press Release – Results of AGM

HBP Press Release – Results of AGM

December 15, 2014

HBP Press Release – Q1 Fiscal 2015 Results

HBP Press Release – Q1 Fiscal 2015 Results

December 4, 2014

Helix BioPharma Corp. to explore growth potential

(Aurora, Ontario) – December 4, 2014 — Helix BioPharma Corp. (TSX, FSE: “HBP”), a
biopharmaceutical company developing innovative drug candidates for the prevention and
treatment of cancer, today announced that the Company has begun a comprehensive exploration
of growth opportunities available to it.

October 23, 2014

HBP Press Release – Fiscal 2014 Results

HBP Press Release – Fiscal 2014 Results

October 23, 2014

2014 Annual Report

September 30, 2014

Helix Reports On Interim Review Of The Polish L-DOS47 Monotherapy Study In Non-Small Cell Lung Cancer

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed its interim data review of the first eight cohorts of the Company’s ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).

September 26, 2014

Helix BioPharma Corp. Initiates Enrollment For Tenth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the tenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).